Meet P3T

Pioneering
First-in-Class Therapies for Chronic Immune-mediated Inflammatory diseases (IMID)

The concept behind our target pathways is based on the Latin phrase:
'Omne trium perfectum' - “Everything that comes in threes is perfect”

Problem

Chronic immune-mediated inflammatory disorders (IMIDs) are among the leading global health threats, second only to cardiovascular diseases like stroke and heart attacks.

In conditions such as Spondyloarthritis (SpA), chronic inflammation is often driven by a compromised gut barrier—commonly referred to as "leaky gut"—and dysbiosis, an imbalance in gut bacteria. These underlying issues lead to persistent inflammation, worsening disease symptoms, and a lack of effective long-term treatments.

Synergistic anti-inflammatory pathways

Our approach combines precise drug delivery systems with Triple Target Activation (TTA) technology, simultaneously activating three key anti-inflammatory pathways. This innovative mechanism ensures maximum therapeutic effect, tackling chronic inflammation at its core and offering a significant advantage over traditional single-target treatments.

First-in-Class Disease-Modifying SCMs

P3T develops new chemical entities (SCMs) specifically designed to target secondary pathways involved in "leaky gut" and other underlying factors of Spondyloarthritis (SpA) and related diseases. These first-in-class, disease-modifying treatments aim to address critical unmet medical needs by providing long-lasting relief and improving patient outcomes.

Biomarker-Driven Development with Organ-on-Chip Technology:

P3T’s biomarker-driven preclinical and clinical development process utilizes cutting-edge "Organ-on-Chip" technology. This platform simulates human tissue behavior, allowing for highly accurate testing of our SCMs and optimizing treatment strategies for better efficacy and safety across different stages of drug development.

Our misson is to develop novel anti-inflammatory, disease-modifying new small chemical molecules (SCM) to address unmet needs in treating Spondyloarthritis (SpA).

Using network pharmacology approach we challenge traditional “one drug”-one target” concept with simultaneous activation of three anti-inflammatory targets (TTA)

Proof-of-Concept Results: TTA Activation by Phytochemicals

Healthy PBMNC’s treated with metformin and, either single, or combination of two or three phytochemicals, incubated for 24 hrs., and afterwards, cells were collected for RT-PCR of designated pro-inflammatory proteins. Since healthy PMBCs do not produce IL-17 it was not tested.

PBMNC’s from two patients with juvenile SpA and healthy controls treated with metformin and, either single, or combination of two or three phytochemicals, incubated for 24 hrs., and afterwards, cells were collected for RT-PCR of designated pro-inflammatory proteins.

IL-10 induction (anti-inflammatory cytokine) in both healthy controls and jSpA patients. Induction was shown for combination of two selected phytochemicals. No TTA was confirmed by combination of three phyotochemicals.

Red square represents triple combination of phytochemicals that are known to activate all three targets (e.g. TTA).
Green square represents combination of two phytochemicals (IL-10 induction)

Triple Target Activation

P3T’s proprietary SCM technology activates three anti-inflammatory targets, providing a revolutionary treatment for chronic immune-mediated inflammatory disorders like Spondyloarthritis (SpA).

AI/ML- assisted Drug Discovery using "anaXa" Platform

Our pipeline runs on breakthrough science. We are currently advancing multiple compelling molecules for the potential treatment of chronic immune-mediated inflammatory diseases (IMID’s).

• “anaXa”: Ancient Greek philosopher Anaxagoras was known for introducing philosophy based on scientific research to Athenians, who were, nevertheless, very skeptical, and not by any means ready to accept such a scientific approach to philosophy.

• Powered by Modalis

Organ-on-Chip Development

Platform will enable biomarker-driven preclinical and clinical trials, ensuring the development of highly effective, first-in-class SCMs for SpA and related diseases.

BUSINESS MODEL 01

Hybrid business model (B2B)

P3T will offer collaboration and licensing opportunities to accelerate drug development, expand pipelines, and bring innovative therapies for immune-mediated inflammatory disorders to market faster.

BUSINESS MODEL 02

In-House Drug Development

Our in-house team drives drug discovery, optimizing SCMs, using AI-driven design, and conducting preclinical testing to ensure safety and efficacy.

BUSINESS MODEL 03

Compound and Biomarker Licensing

We will provide licensing for novel compounds and biomarker technologies targeting immune-mediated diseases, offering partners access to groundbreaking innovations for their pipelines.

Unlocking a High-Growth Opportunity in Precision Medicine

Large and Growing Market Opportunity

The global SpA market is projected to grow from $5.32 billion in 2023 to $8.79 billion by 2030, with over 50 million affected worldwide. P3T’s solutions target this rapidly expanding market.

Differentiated, First-in-Class Technology

P3T’s Triple Target Activation (TTA) offers a novel, disease-modifying approach by targeting three pathways, addressing "leaky gut" and inflammation, validated through preclinical studies.

High Growth Potential with Minimal Initial Investment

P3T provides high-return potential with low initial investment, offering multiple pathways for commercialization through collaborative development, out-licensing, and biomarker licensing.

Possible other indications

Miroslav Harjaček

Founder and executive chairman

Inflammatory bowel disease (IBD)

Reversing "leaky gut" and disrupted tight junctions (TJ)

Rheumatoid Arthritis

Modulating immune response to reduce joint inflammation.

InflammAGING

Addressing age-related inflammation for improved health.

Cellulite

Innovative therapies reducing inflammation behind cellulite.

Pipeline (in silico)

Roadmap

Frequently Asked Questions

Made by the best minds in the industry.

Founder and Executive Chairman

Miroslav Harječek

Serial entrepreneur, Professor of Pediatrics, MD PhD, and author of many scientific projects with more than 30years of experience as a practicing Pediatric Rheumatologist.

CoFounder and CEO

Dario Naletilić

MD and business consultant
Big Pharma executive with more than 30 years of experience HC management instructor.

PoC Leader

Ernest Meštrović

Professor of Chemistry and Vice Dean at the Faculty of Chemical Engineering and Technology.

Leading data scientist

Zlatko Smole, PhD

Molecular biologist.

Ready to invest?

Feel free to send us an email and we will get back to you in the shortest possible time!

Sections

Mission Problem & Solution Business Model Opportunity Faq About Us

Company info

info@p3therapeutics.eu

P 3 Therapeutics d.o.o.
Balokovićeva ulica 51
10000 Zagreb, Croatia
OIB: 63459594863

Contact

+385 91 467 3116

mharjacek@p3therapeutics.eu

Made by Differo.

PioneeringFirst-in-Class Therapies for Chronic Immune-mediated Inflammatory diseases (IMID)